SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
Silvio Danese 1
Jean-Frédéric Colombel 2
Steve Hanauer 3
William J. Sandborn 4
Bruce E. Sands
Stefan Schreiber 5
Sang Joon Lee 6
Sung Hyun Kim
Yun Ju Bae
Sun Hee Lee
Seul Gi Lee
JoonHo Lee
Jong Min Kim
SIYOUNG YANG
Jimin Lee
Gahee Park
Juhyun Lee
1 IRCCS San Raffaele Scientific Institute, Milan, Italy
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Northwestern University/ Feinberg School of Medicine, Chicago, IL, United States
4 University of California San Diego, La Jolla, United States
5 University Hospital Schleswig-Holstein, Kiel, Germany
6 Celltrion, Inc, Incheon, Korea, Republic of
Topic
IBD
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]